Clinical trial
TBTC Study 23B:Intensive Pharmacokinetics of the Nelfinavir Rifabutin Interaction in Patients With HIV-Related Tuberculosis Treated With a Rifabutin-Based Regimen
NCT00023400 is registered in ClinicalTrials.gov with Centers for Disease Control and Prevention as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- TBTC Study 23B:Intensive Pharmacokinetics of the Nelfinavir Rifabutin Interaction in Patients With HIV-Related Tuberculosis Treated With a Rifabutin-Based Regimen
- Lead sponsor
- Centers for Disease Control and Prevention
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- February 29, 2000
- Completion date
- February 28, 2002
- Enrollment
- 20
- Sites
- 23
Conditions
As the registry lists them; a condition with its own page is linked.